Ad
Monday, 12 March 2018
Impax faces U.S. antitrust trial over generic acne drug's delay
BOSTON (Reuters) - Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment